Orforglipron
LY3502970 (oral non-peptide GLP-1)
Orforglipron (LY3502970 (oral non-peptide GLP-1)) is a metabolic & fat loss research compound. First oral small-molecule (non-peptide) GLP-1 agonist — cAMP-biased partial agonist; food-independent absorption, no injection.
Orforglipron quick facts
| Reported research dose | 3mg-36mg (titrated) |
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | ~25-35 hrs |
| Forms | Oral |
| Evidence level | Phase 3 human (positive) |
A genuine game-changer — pill-form GLP-1 with injectable-level results. Watch this space.
How Orforglipron works
First oral small-molecule (non-peptide) GLP-1 agonist — cAMP-biased partial agonist; food-independent absorption, no injection.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get Orforglipron
Buy Orforglipron at Flawless Compounds →The evidence for Orforglipron
Graded by what exists behind each claim.
✅ Clinically validated
- Phase 3 complete, with regulatory submission underway. Eli Lilly's oral, non-peptide GLP-1 agonist. The ACHIEVE and ATTAIN programs reported HbA1c reduction in type 2 diabetes and weight loss in the 11–12% range at 72 weeks in obesity.
- Read the number in context: it is below injectable semaglutide and well below tirzepatide, and above oral semaglutide. The trade is convenience against magnitude, not a new efficacy ceiling.
📊 Correlative data
- Not yet marketed. Trial discontinuation rates from GI effects were meaningful and dose-related, consistent with the class.
🧪 Theoretical / extrapolated
- A small molecule, not a peptide — which is the whole story. Peptides are destroyed by digestion, which is why oral semaglutide needs an absorption enhancer and still achieves roughly 1% bioavailability with strict fasting requirements.
- A non-peptide agonist sidesteps all of that: no injection, no absorption enhancer, no food-timing restrictions, and manufacturing at chemical rather than biological cost. That last point is why this molecule matters for access even though its effect size is not class-leading.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Orforglipron actually does
Every other GLP-1 drug in this catalog is a peptide. This one is not, and that single fact generates everything else on the page. Orforglipron is a non-peptide small molecule, and it does not bind where GLP-1 binds. The cryo-EM structure puts it in a pocket in the upper helical bundle formed by the receptor’s extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3 and 7 Kawai 2020. A 31-residue peptide hormone drapes across the orthosteric site; this molecule sits in a crevice above it and pushes the same machine from a different lever.
It is a partial agonist, and it is biased. The same work reports partial agonism at the GLP-1 receptor with signaling biased toward G protein activation over beta-arrestin recruitment Kawai 2020. Beta-arrestin is the arm that internalizes and desensitizes a receptor after it fires. A molecule that activates the G protein and recruits little arrestin is, in principle, one that keeps a receptor at the surface for longer — and a partial agonist is one that cannot drive the receptor as hard as the full peptide can even at saturating concentration. Those two properties pull in opposite directions on efficacy, and the clinical numbers further down this page are what that tension looks like in a person.
The strangest fact about this drug, and it is a structural one. The binding pocket depends on an interaction with Trp33 of the receptor’s extracellular domain — a residue that is primate-specific Kawai 2020. A rat or a wild-type mouse does not have it. So this compound does not activate the ordinary rodent GLP-1 receptor, and its whole preclinical package had to be rebuilt: efficacy was shown in humanized GLP-1R transgenic mice and in non-human primates, where the effect size on glucose, insulin secretion and food intake was reported as comparable to injectable exenatide Kawai 2020.
That is not a footnote. Almost every safety intuition the research market has about GLP-1 drugs — rodent thyroid C-cell findings included — comes from experiments in animals whose receptor this molecule cannot bind. The on-target rodent data that exist for the peptides simply do not transfer to it, in either direction.
And the practical consequence of not being a peptide. There is nothing for a protease to cut, no charge problem at the enterocyte, and no need for a permeation enhancer. The absolute oral bioavailability is 79.1% ± 16.8% Morse 2025. For comparison, the only marketed oral peptide in this class is absorbed at well under one percent of the swallowed dose. That gap of roughly two orders of magnitude is the reason this molecule exists.
Cell, rodent, human — and where it stops
Step one, structure and cells. Cryo-EM of the molecule-bound GLP-1 receptor, partial agonism, G-protein bias, and the primate-specific Trp33 contact Kawai 2020.
Step two, animals — but only the ones that were rebuilt. Oral dosing lowered glucose in humanized GLP-1R transgenic mice, and produced insulinotropic and hypophagic effects in non-human primates, with an effect size comparable to injectable exenatide in both models Kawai 2020.
Step three, human pharmacokinetics, and this is the part of the record that is genuinely unusual. Two phase 1 open-label studies in healthy adults using a [14C] radiolabel: absolute oral bioavailability 79.1% ± 16.8%; elimination overwhelmingly fecal, 87% ± 2.8%, with urinary excretion of 0.2% ± 0.02%; total recovery 88% over 384 hours; and in plasma the parent drug was 93.3% of circulating drug-related material, with minor oxidative metabolites M7 at 3.3% and M23 at 1.6% Morse 2025.
Step four, the food question, which is the second reason this drug is not oral semaglutide. Two phase 1 randomized crossover studies: a single 3 mg dose in 12 participants (mean age 45.0, 66.7% male) and multiple 16 mg doses in 34 participants (mean age 42.8, 88.2% male). Fed versus fasted, geometric least-squares mean AUC and Cmax were lower by 23.7% and 23.2% in the first study and 17.6% and 20.9% in the second, and the authors concluded the difference is unlikely to be clinically meaningful — hence no prandial restrictions Ma 2024.
Step five, phase 3 ATTAIN-2, which met its primary endpoint. 1,613 participants (757, 46.9%, female) with obesity or overweight and type 2 diabetes, mean baseline HbA1c 8.05%, randomized to orforglipron 6 mg (n = 329), 12 mg (n = 332), 36 mg (n = 322) or placebo (n = 630) for 72 weeks (NCT05872620). Primary endpoint: mean percent change in body weight at week 72. Result: −5.1%, −7.0% and −9.6% against −2.5% on placebo, estimated treatment differences −2.7, −4.5 and −7.1 percentage points, all P < 0.0001 Horn 2025.
Step six, approval and the liver database. Orforglipron was approved in the USA in April 2026 for long-term weight management in adults with obesity, or overweight with a weight-related comorbidity Shirley 2026. A pooled hepatic safety analysis across seven phase 3 trials and 11,220 participants (6,920 on orforglipron, 4,300 on comparator, exposure up to 104 weeks) found ALT or AST at least three times the upper limit of normal together with total bilirubin at least twice normal in 6 participants (0.1%) on drug and 6 (0.1%) on comparator Wharton 2026.
The obstacles, one at a time. (1) The pivotal trial on this page enrolled people with type 2 diabetes, a population in which every weight-loss drug ever tested loses less weight than in obesity without diabetes Horn 2025. Comparing −9.6% against a semaglutide obesity number is comparing two different populations. (2) Partial agonism is the plausible ceiling Kawai 2020 and no trial has tested that directly by pushing dose until the curve flattens. (3) No head-to-head against an injectable. (4) No wild-type rodent on-target data exist and cannot, because of Trp33 Kawai 2020. (5) The food-effect conclusion rests on 46 people across two crossover studies Ma 2024, which is a normal size for that design and a small one for a claim used every day by every user.
Orforglipron pharmacokinetics — how much of it actually gets in
This is the only compound in this cohort whose pharmacokinetics are the reason it exists, and the numbers are all published. The card says ~25–35 hours and oral, which fits once-daily dosing.
Absolute oral bioavailability: 79.1% ± 16.8%, measured against an intravenous [14C] microdose Morse 2025. Nearly four fifths of a swallowed tablet reaches the systemic circulation. Nothing else in this catalog that is taken by mouth has a number remotely like it, and the reason is negative rather than clever: there is no peptide bond for a protease to hydrolyze, no need for an absorption enhancer, and consequently very little first-pass loss.
What clears it, and where it goes. 87% ± 2.8% fecal, 0.2% ± 0.02% urinary, total recovery 88% across 384 hours Morse 2025. Two consequences follow directly. First, this is a biliary/fecal drug — renal impairment is not the obvious dose-adjustment axis it would be for a renally cleared molecule. Second, a collection window that had to run 16 days to recover 88% is consistent with a long terminal phase behind the once-daily dosing interval.
What metabolizes it, and why this matters more than it does for a peptide. Parent drug was 93.3% of circulating drug-related material, with oxidative metabolites M7 (3.3%) and M23 (1.6%) Morse 2025. Oxidative metabolism means cytochrome P450 enzymes, which means this molecule lives in a world of drug–drug interactions that injectable peptides simply do not have. A peptide’s only meaningful interaction is delayed gastric emptying changing how fast something else is absorbed. A small molecule cleared oxidatively can also have its own concentration moved by whatever else is in the cabinet.
The food effect, stated as a number rather than as ‘take it any time’. Fed versus fasted exposure is 17.6% to 23.7% lower, with Cmax 20.9% to 23.2% lower Ma 2024. The regulatory reading is that this is not clinically meaningful, and that is a defensible reading. The practical reading is different: a person who takes it with breakfast every day is running roughly a fifth less exposure than the same person taking it fasted, and someone who alternates is adding a 20% swing to their own dose. Consistency is free and it is the only handle a user has on this variable.
The route, and what it removes. There is no injection, no reconstitution, no diluent to buy, no cold chain and no needle. For a research-market buyer that removes most of the failure modes that the rest of this catalog is built around — and replaces them with a different one, which is that a tablet of unknown provenance contains an unknown mass of an unknown compound and there is no cloudiness to warn you.
What would have to be true, and how you would know it was not
Four predictions. The second says this drug should underperform the injectables, which is the opposite of how it is sold.
1. HbA1c and fasting insulin should both fall, and HbA1c is the faster of the two to trust. Baseline HbA1c in the pivotal trial was 8.05% and glycemic measures improved significantly at every dose Horn 2025. Draw HbA1c and fasting insulin at baseline, 12 and 24 weeks. HbA1c is an integral over about three months, so a 12-week retest is the first honest one.
2. Weight loss will land below what an injectable GLP-1 produces, and this cuts against the compound. At the top 36 mg dose over 72 weeks the result was −9.6% Horn 2025. The mechanistic reason to expect a ceiling is partial agonism Kawai 2020: a partial agonist cannot drive a receptor to the same maximum as the full peptide no matter how much of it you give. The falsification is straightforward for anyone who has used an injectable before — same person, same diet, same 24-week window, and if the oral matches or beats their own injectable trajectory, the partial agonism argument is wrong.
3. ALT and GGT should fall in proportion to weight lost and not more. The pooled phase 3 hepatic analysis describes aminotransferase trajectories as consistent with the metabolic benefits of weight loss Wharton 2026, which is a claim about consequence rather than about a hepatic drug effect. Draw a CMP and GGT at baseline and 24 weeks and plot the change against kilograms lost. A fall steeper than the weight explains would be new information; the prediction is that there is not one.
4. The dosing-consistency experiment, which costs nothing. Exposure is 17.6–23.7% lower fed than fasted Ma 2024. Take it at the same time relative to food for eight weeks, then switch the relationship for eight weeks, holding dose constant, and track nausea severity and appetite on a fixed daily scale. If peak concentration drives the gastrointestinal effects — which is the standard explanation in this class — the fasted block should be the harder one.
What nobody has tested yet
Five experiments. The third is a hole in the safety literature that nobody outside the sponsor seems to have noticed.
1. Nobody has run this against an injectable at maximal doses. The partial-agonism hypothesis Kawai 2020 predicts a lower ceiling than a full agonist, and the entire commercial argument for the drug is convenience rather than efficacy. One head-to-head with a prespecified non-inferiority margin would settle what everybody is currently guessing from cross-trial comparisons in different populations.
2. Nobody has published whether G-protein bias buys durability. Reduced beta-arrestin recruitment Kawai 2020 is the standard argument for less receptor internalization and less tachyphylaxis. Nothing in the published trial record tests it: that would need receptor-level pharmacodynamics at week 4 against week 72, and no such measurement has been reported.
3. The rodent problem has never been publicly resolved. Because the pocket depends on the primate-specific Trp33, this molecule cannot activate a wild-type rodent GLP-1 receptor Kawai 2020. Two-year rodent carcinogenicity work is the conventional route to the thyroid C-cell question for this class, and it cannot be done on-target in an ordinary rat for this compound. Whatever was substituted — humanized animals, a different species, or an argument from receptor distribution — is not in the indexed literature this page can read.
4. Nobody has measured the food effect at the top dose. The crossover work used 3 mg and 16 mg Ma 2024; the pivotal efficacy dose is 36 mg Horn 2025. Absorption effects are not always dose-proportional, and the one clinically useful instruction this drug gives its users rests on doses less than half the one they will end up taking.
5. Nobody has published its cytochrome interaction profile in a way a user can act on. Oxidative metabolites M7 and M23 are reported Morse 2025; which enzymes make them, and what happens when an inhibitor or inducer of those enzymes is co-administered, is not in the abstract record. For a daily oral drug taken by people who also take other daily oral drugs, that is the most practically important missing table.
Orforglipron — its own safety story, not its class's
The class block on this page is written for injectable GLP-1 peptides. Five things below are specific to an oral small molecule.
1. The liver question was asked deliberately, and the answer is reassuring so far. A pooled analysis of seven phase 3 trials, 11,220 participants, exposure to 104 weeks, found the combination of ALT or AST at least 3× the upper limit of normal with bilirubin at least 2× normal in 0.1% on drug and 0.1% on comparator Wharton 2026. Sponsors do not pool seven trials for a hepatic endpoint unless the question was live; that it was asked and answered at this scale is more informative than a silent record would be.
2. Gastrointestinal events cluster in escalation. In the pivotal trial they were mild to moderate and predominantly occurred during dose escalation, with discontinuation for adverse events at 6.1–9.9% on drug against 4.1% on placebo Horn 2025. Roughly one in fifteen people stopped for a side effect; that is the honest denominator.
3. A tablet is easier to get wrong than an injection. With 79.1% oral bioavailability Morse 2025, a doubled dose is very nearly a doubled exposure — there is no absorption ceiling to absorb the error, which is exactly what protects an oral peptide from the same mistake. Every milligram swallowed counts.
4. This one has drug interactions and the peptides do not. Oxidative metabolism Morse 2025 places it in the cytochrome world. That is a category of risk the rest of this catalog’s GLP-1 entries genuinely do not carry, and it is the thing to check before adding it to an existing prescription list rather than after.
5. What approval does and does not buy. First approval was in April 2026 Shirley 2026. The safety database behind that is trial-sized and trial-length: 11,220 participants and up to 104 weeks Wharton 2026. Rare events at population scale, and anything with a latency longer than two years, are by definition not in it yet, and the research-market version of this compound — a tablet of unverified content — is not the drug those 11,220 people took.
Sources read for this page
- Kawai T, et al. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences 2020 · PMID 33177239
- Morse BL, et al. Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants. Clinical Pharmacology in Drug Development 2025 · PMID 40888509
- Ma X, et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Therapy 2024 · PMID 38402332
- Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet 2025 · PMID 41275875
- Wharton S, et al. Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials. Diabetes, Obesity and Metabolism 2026 · PMID 42338042
- Shirley M. Orforglipron: First Approval. Drugs 2026 · PMID 42479349
Orforglipron — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Orforglipron — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Orforglipron moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Orforglipron in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Orforglipron
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Baseline before an oral GLP-1 |
| Fasting Insulin | Where the change appears first |
| Lipase | Pancreatitis monitoring |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Orforglipron — frequently asked questions
What is Orforglipron?
Orforglipron (LY3502970 (oral non-peptide GLP-1)) is a metabolic & fat loss research compound. First oral small-molecule (non-peptide) GLP-1 agonist — cAMP-biased partial agonist; food-independent absorption, no injection.
Is the full Orforglipron protocol on this page?
The reported research dose is on this page, along with how Orforglipron works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Orforglipron?
Orforglipron has an approximate half-life of ~25-35 hrs, which is part of what determines how often it's dosed.
What's the evidence behind Orforglipron?
Current evidence level: Phase 3 human (positive). Orforglipron is offered for research purposes only and is not an approved medicine.
Orforglipron inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Orforglipron is used for
Orforglipron appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
Orforglipron is the appetite arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.